Why the study?
Does abciximab-modified thrombelastography correlate with plasma fibrinogen levels and platelet count in patients undergoing coronary revascularization?
Population
Patients undergoing coronary revascularization (cardiac surgery)
Comparison
Abciximab-modified thrombelastography (TEG) vs Standard thrombelastography and standard…
Design
Cross-sectional
Authors
Loading...
May aid differentiation of fibrinogen versus platelet contributions to clot strength; hypothesis-generating for TEG-guided transfusion in cardiac surgery.
Does abciximab-modified thrombelastography correlate with plasma fibrinogen levels and platelet count in patients undergoing coronary revascularization?
Abciximab-modified thrombelastography can help discriminate between hypofibrinogenemia and platelet dysfunction as causes of decreased clot strength in cardiac surgery patients.
Kettner et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: